article thumbnail

Medicare to Cover Weight-Loss Drug Wegovy for Certain Patients

Med Page Today

(MedPage Today) -- Medicare will cover the weight-loss drug semaglutide (Wegovy) under its Part D drug program for patients with overweight or obesity who have preexisting heart disease and need the drug to prevent heart attacks or strokes, the.

Medicare 132
article thumbnail

The heart of the question: Who can get Medicare-covered weight loss medicine?

Science Daily - Heart Disease

With Medicare now covering semaglutide for people with obesity and cardiovascular disease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription plans apply.

Medicare 130
article thumbnail

One in 7 Medicare beneficiaries with high body mass index may qualify for anti-obesity drug

Science Daily - Heart Disease

million Medicare beneficiaries are most likely to become eligible for semaglutide. If Medicare Part D narrowly defines cardiovascular disease, majority of patients would remain ineligible while new federal spending could still exceed $10 billion. A new study estimates that 3.6

article thumbnail

STS Announces Late-breaker Research to Be Presented at the 2024 Annual Meeting

DAIC

The researchers found that Medicare patients undergoing esophagectomy for cancer exhibit identifiable predictors for long-term survival and readmission. These findings suggest opportunities to enhance clinical practice and improve outcomes for Medicare patients undergoing esophagectomy for cancer.

Research 111
article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

The breakthrough designation, according to the Milpitas, CA-based technology company, is for an indication to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions.

article thumbnail

HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease (CAD) with FFRCT Analysis

DAIC

3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives. Since its inception, HeartFlow has been committed to building a new standard of care for people at risk of heart disease. Arbab-Zadeh, Heart Int 2012. For more information: www.heartflow.com References 1. Yokota, et al.

article thumbnail

Cardiac Wire’s Top 8 Takeaways from ACC 2024

CardiacWire

GLP-1s Are So Hot Right Now – In the year since ACC 2023, GLP-1s went from a weight loss and diabetes drug that “might” have cardiovascular benefits to becoming a promising (and Medicare-covered) option for CV event reduction.